

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

August 28, 2025

Ilan Hadar Chairman and Chief Executive Officer Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606

> Re: Silexion Therapeutics Corp Registration Statement on Form S-1 Filed August 26, 2025 File No. 333-289860

Dear Ilan Hadar:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Daniel Crawford at 202-551-7767 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Jonathan M. Nathan, Esq.